The genetic basis of Parkinson's disease.

Pesticides and Parkinson's disease--is there a link? Environ Health Perspect (2006) 2.01

Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. J Neurol (2009) 1.27

Association between the ubiquitin carboxyl-terminal esterase L1 gene (UCHL1) S18Y variant and Parkinson's Disease: a HuGE review and meta-analysis. Am J Epidemiol (2009) 1.08

Angiotensin II protects against alpha-synuclein toxicity and reduces protein aggregation in vitro. Biochem Biophys Res Commun (2007) 0.79

Early exposure to paraquat sensitizes dopaminergic neurons to subsequent silencing of PINK1 gene expression in mice. Int J Biol Sci (2011) 0.78

Parkinson's disease without tremor masquerading as mechanical back pain; a case report. J Can Chiropr Assoc (2008) 0.77

Tricyclic Antidepressants Amitriptyline and Desipramine Induced Neurotoxicity Associated with Parkinson's Disease. Mol Cells (2015) 0.75

Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry (1992) 33.67

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30

Alpha-synuclein in Lewy bodies. Nature (1997) 20.83

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92

Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62

Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet (2000) 7.83

Introduction to sample size determination and power analysis for clinical trials. Control Clin Trials (1981) 6.06

What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology (1992) 6.03

Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc Natl Acad Sci U S A (2000) 5.83

Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72

Parkinson disease in twins: an etiologic study. JAMA (1999) 5.45

Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci (2001) 5.32

Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98

Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001) 4.48

The ubiquitin pathway in Parkinson's disease. Nature (1998) 4.48

Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science (2001) 4.18

Mapping of a gene for Parkinson's disease to chromosome 4q21-q23. Science (1996) 3.79

A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. Ann Neurol (2002) 3.00

Vesicle permeabilization by protofibrillar alpha-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry (2001) 2.96

Complete genomic screen in Parkinson disease: evidence for multiple genes. JAMA (2001) 2.79

The proteasome, a novel protease regulated by multiple mechanisms. J Biol Chem (1999) 2.72

Parkinson's disease, pesticides, and glutathione transferase polymorphisms. Lancet (1998) 2.65

Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology (1983) 2.47

Familial aggregation of Parkinson's disease in Iceland. N Engl J Med (2000) 2.41

Association of single-nucleotide polymorphisms of the tau gene with late-onset Parkinson disease. JAMA (2001) 2.36

Isolated tremor and disruption of the nigrostriatal dopaminergic system: an 18F-dopa PET study. Neurology (1992) 2.36

Research diagnostic criteria for Parkinson's disease. Adv Neurol (1990) 2.28

Increased risk of Parkinson's disease in parents and siblings of patients. Ann Neurol (1994) 2.19

Substrate specificity of deubiquitinating enzymes: ubiquitin C-terminal hydrolases. Biochemistry (1998) 2.18

alpha-Synuclein gene haplotypes are associated with Parkinson's disease. Hum Mol Genet (2001) 2.07

Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci (2001) 2.04

Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism. J Am Geriatr Soc (1969) 2.01

The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol (1999) 1.85

A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nat Genet (1998) 1.84

Neuroleptic medications inhibit complex I of the electron transport chain. Ann Neurol (1993) 1.82

Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36. Am J Hum Genet (2001) 1.72

Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. Am J Hum Genet (2001) 1.71

PARK6-linked parkinsonism occurs in several European families. Ann Neurol (2002) 1.68

A Greek-American kindred with autosomal dominant, levodopa-responsive parkinsonism and anticipation. Ann Neurol (1995) 1.64

Genetic classification of primary neurodegenerative disease. Science (1998) 1.52

A genetic polymorphism of MAO-B modifies the association of cigarette smoking and Parkinson's disease. Neurology (1998) 1.52

Ubiquitin carboxyl-terminal hydrolase (PGP 9.5) is selectively present in ubiquitinated inclusion bodies characteristic of human neurodegenerative diseases. J Pathol (1990) 1.51

A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor. Hum Mol Genet (1999) 1.43

Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet (1997) 1.43

Positron emission tomographic analysis of the nigrostriatal dopaminergic system in familial parkinsonism associated with mutations in the parkin gene. Ann Neurol (2001) 1.42

Environmental, medical, and family history risk factors for Parkinson's disease: a New England-based case control study. Am J Med Genet (1999) 1.42

Cigarette smoking and protection from Parkinson's disease: false association or etiologic clue? Neurology (1995) 1.40

Selegiline and Parkinson's disease: it's déjà vu-again. Neurology (2000) 1.37

Risk of Parkinson's disease among first-degree relatives: A community-based study. Neurology (1996) 1.30

Familial aggregation of Parkinson's disease: a population-based case-control study in Europe. EUROPARKINSON Study Group. Neurology (1999) 1.29

Genome-wide scan for Parkinson's disease: the GenePD Study. Neurology (2001) 1.25

Parkinson's disease: a test of the multifactorial etiologic hypothesis. Neurology (1993) 1.25

Parkinson's disease in twins studied with 18F-dopa and positron emission tomography. Neurology (1992) 1.24

Clinical genetic analysis of Parkinson's disease in the Contursi kindred. Ann Neurol (1996) 1.24

New data on the genetics of Parkinson's disease. Can J Neurol Sci (1982) 1.18

Variability and validity of polymorphism association studies in Parkinson's disease. Neurology (2000) 1.14

Familial Parkinson's disease: a clinical genetic analysis. Can J Neurol Sci (1995) 1.13

Parkinson's disease. A genetic study. Brain (1973) 1.13

Environmental and genetic risk factors in Parkinson's disease: a case-control study in southern Italy. Mov Disord (1996) 1.11

Mitochondrial dysfunction in idiopathic Parkinson disease. Am J Hum Genet (1998) 1.04

Low frequency of pathogenic mutations in the ubiquitin carboxy-terminal hydrolase gene in familial Parkinson's disease. Neuroreport (1999) 1.04

Matrilineal inheritance of complex I dysfunction in a multigenerational Parkinson's disease family. Ann Neurol (1998) 1.04

A clinical genetic study of Parkinson's disease: evidence for dominant transmission. Neurology (1994) 1.04

Parkinson's disease in twins. J Neurol Neurosurg Psychiatry (1987) 1.02

Twin studies and the genetics of Parkinson's disease--a reappraisal. Mov Disord (1990) 1.01

Polymorphism of NACP-Rep1 in Parkinson's disease: an etiologic link with essential tremor? Neurology (2000) 0.97

Parkinson's disease in a nationwide twin cohort. Neurology (1988) 0.96

Genetic anticipation in Parkinson's disease. Neurology (1995) 0.95

A clinical and genetic study of familial Parkinson's disease. Mov Disord (1991) 0.94

Twin study of Parkinson disease. Neurology (1981) 0.93

Metabolism of MPTP by cytochrome P4502D6 and the demonstration of 2D6 mRNA in human foetal and adult brain by in situ hybridization. Xenobiotica (1997) 0.93

Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch Neurol (2001) 0.92

Case-control study of interactions between genetic and environmental factors in Parkinson's disease. Lancet (1999) 0.92

Mitochondrial dysfunction in Parkinson's disease. Ann Neurol (1998) 0.91

Parkinson's disease is not associated with the combined alpha-synuclein/apolipoprotein E susceptibility genotype. Ann Neurol (2001) 0.89

Meta-analysis of studies of the CYP2D6 polymorphism in relation to lung cancer and Parkinson's disease. Pharmacogenetics (1998) 0.88

Gene-toxin interaction as a putative risk factor for Parkinson's disease with dementia. Neuroepidemiology (1998) 0.87

A kindred with Parkinson's disease not showing genetic linkage to established loci. Neurology (2000) 0.87

The distribution of ancestral secondary cases in Parkinson's disease. Clin Genet (1977) 0.87

No evidence for association of familial Parkinson's disease with CAG repeat expansion. Neurology (1995) 0.86

The alpha-synuclein gene and Parkinson disease in a Chinese population. Arch Neurol (2000) 0.85

A clinical and genetic study of familial cases of Parkinson's disease. J Neurol Sci (1995) 0.85

"Familial Parkinson's disease"--a case-control study of families. Can J Neurol Sci (1997) 0.84

Linkage exclusion in French families with probable Parkinson' s disease. Mov Disord (2000) 0.83

Segregation analysis of Parkinson disease. Am J Med Genet (1998) 0.83

Neuroscience. Parkin and its substrates. Science (2001) 0.82

No genetic association of the ubiquitin carboxy-terminal hydrolase-L1 gene S18Y polymorphism with familial Parkinson's disease. J Neural Transm (Vienna) (2001) 0.82

Genetic linkage analysis. Arch Neurol (1999) 0.82

Association study of dopamine receptor gene polymorphisms with drug-induced hallucinations in patients with idiopathic Parkinson's disease. Pharmacogenetics (2000) 0.82

Mutations in the alpha-synuclein gene in Parkinson's disease among Indians. Acta Neurol Scand (2001) 0.81

Tau and Parkinson disease. JAMA (2001) 0.79

The alpha-synuclein gene is not a major risk factor in familial Parkinson disease. Neurogenetics (1999) 0.78

Increased risk of Parkinson's disease in relatives of patients. Ann Neurol (1995) 0.78

Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study. Brain (2002) 0.78

The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease. Neurosci Lett (1999) 0.77

The clinicopathologic spectrum of Lewy body disease. Adv Neurol (1996) 0.76

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat Genet (2013) 9.46

A functional role for adult hippocampal neurogenesis in spatial pattern separation. Science (2009) 6.62

The prevalence of frontotemporal dementia. Neurology (2002) 5.73

Mild cognitive impairment in Parkinson disease: a multicenter pooled analysis. Neurology (2010) 4.06

Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology (1999) 3.95

The prevalence of dementia in Europe: a collaborative study of 1980-1990 findings. Eurodem Prevalence Research Group. Int J Epidemiol (1991) 3.70

Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex (2001) 3.67

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain (2007) 3.62

Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry (2005) 2.54

The MHC haplotype project: a resource for HLA-linked association studies. Tissue Antigens (2002) 2.16

HLA-DRB1 and multiple sclerosis in Malta. Neurology (2007) 2.14

Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group. Neurology (1999) 2.13

Frequency and distribution of Alzheimer's disease in Europe: a collaborative study of 1980-1990 prevalence findings. The EURODEM-Prevalence Research Group. Ann Neurol (1991) 1.89

Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology (2006) 1.88

Dementia and survival in Parkinson disease: a 12-year population study. Neurology (2008) 1.86

Alpha-2 macroglobulin polymorphism and Alzheimer disease risk in the UK. Nat Genet (1999) 1.79

Unilateral transplantation of human primary fetal tissue in four patients with Huntington's disease: NEST-UK safety report ISRCTN no 36485475. J Neurol Neurosurg Psychiatry (2002) 1.76

Incidence of early-onset dementias in Cambridgeshire, United Kingdom. Neurology (2008) 1.76

Mechanisms of cognitive set flexibility in Parkinson's disease. Brain (2001) 1.71

Incidence of dementia in a population older than 75 years in the United Kingdom. Arch Gen Psychiatry (1994) 1.66

Mild cognitive impairment: a concept in evolution. J Intern Med (2014) 1.65

BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson's disease. J Neurol Neurosurg Psychiatry (2008) 1.63

Stroke, vascular risk factors and depression: Cross-sectional study in a UK Caribbean-born population. Br J Psychiatry (2001) 1.62

The impact on prevalence of dementia in the oldest age groups of differential mortality patterns: a deterministic approach. Int J Epidemiol (1998) 1.62

CAMCOG--a concise neuropsychological test to assist dementia diagnosis: socio-demographic determinants in an elderly population sample. Br J Clin Psychol (1995) 1.62

Exploring the impact of prevalence and mortality on incidence of dementia in the oldest old: the sensitivity of a deterministic approach. Neuroepidemiology (2001) 1.60

A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand (2006) 1.49

Increased fructose intake as a risk factor for dementia. J Gerontol A Biol Sci Med Sci (2010) 1.48

Cognition and survival: an exploration in a large multicentre study of the population aged 65 years and over. Int J Epidemiol (2001) 1.48

Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. Tissue Antigens (2004) 1.47

Are trials of intravascular infusions of autologous mesenchymal stem cells in patients with multiple system atrophy currently justified, and are they effective? Clin Pharmacol Ther (2008) 1.45

Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. Brain (2009) 1.43

Effect of smoking on global cognitive function in nondemented elderly. Neurology (2004) 1.42

[Neuralgic amyotrophy]. Tidsskr Nor Laegeforen (1998) 1.39

Profile of disability in elderly people: estimates from a longitudinal population study. BMJ (1999) 1.38

The utility of the Cambridge Behavioural Inventory in neurodegenerative disease. J Neurol Neurosurg Psychiatry (2007) 1.37

Astrocyte phenotype in relation to Alzheimer-type pathology in the ageing brain. Neurobiol Aging (2008) 1.35

Population norms for the MMSE in the very old: estimates based on longitudinal data. Mini-Mental State Examination. Neurology (2000) 1.35

Profile of cognitive progression in early Huntington's disease. Neurology (2003) 1.35

Patterns and stages of alpha-synucleinopathy: Relevance in a population-based cohort. Neurology (2008) 1.32

No evidence for association with Parkinson disease for 13 single-nucleotide polymorphisms identified by whole-genome association screening. Am J Hum Genet (2006) 1.31

Smoking, drinking, and other life style factors and cognitive function in men in the Caerphilly cohort. J Epidemiol Community Health (1999) 1.30

Parkinson's disease and dopaminergic therapy--differential effects on movement, reward and cognition. Brain (2008) 1.29

Staging of cytoskeletal and beta-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol (2000) 1.28

Factors associated with functional decline and improvement in a very elderly community-dwelling population. Am J Epidemiol (1999) 1.22

Staging and preparation of human fetal striatal tissue for neural transplantation in Huntington's disease. Cell Transplant (2003) 1.20

Setting the minimal metrically detectable change on disability rating scales. Arch Phys Med Rehabil (1997) 1.19

Biomarkers and Parkinson's disease. Brain (2004) 1.17

Neuropathological findings in the very old. Results from the first 101 brains of a population-based longitudinal study of dementing disorders. Ann N Y Acad Sci (2000) 1.17

Suggestive evidence for association of human chromosome 18q12-q21 and its orthologue on rat and mouse chromosome 18 with several autoimmune diseases. Diabetes (2001) 1.17

Dynamic causal modelling of effective connectivity from fMRI: are results reproducible and sensitive to Parkinson's disease and its treatment? Neuroimage (2010) 1.17

White matter lesions in an unselected cohort of the elderly: astrocytic, microglial and oligodendrocyte precursor cell responses. Neuropathol Appl Neurobiol (2007) 1.14

Exploring the dense mapping of a region of potential linkage in complex disease: an example in multiple sclerosis. Genet Epidemiol (1999) 1.13

Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol (2010) 1.13

Intentional weight loss in overweight and obese individuals and cognitive function: a systematic review and meta-analysis. Obes Rev (2011) 1.12

Genome-wide association study of Alzheimer's disease with psychotic symptoms. Mol Psychiatry (2011) 1.11

The ACE gene and Alzheimer's disease susceptibility. J Med Genet (2000) 1.11

Weight changes in Huntington's disease. Eur J Neurol (2006) 1.10

Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. J Neurol Neurosurg Psychiatry (2008) 1.09

The epidemiology of Parkinson's disease in an Australian population. Neuroepidemiology (1998) 1.08

Depression, APOE genotype and subjective memory impairment: a cross-sectional study in an African-Caribbean population. Psychol Med (2001) 1.08

Aging and lymphocyte subpopulations: whole-blood analysis of immune markers in a large population sample of healthy elderly individuals. Exp Gerontol (1998) 1.07

The genetics of multiple sclerosis: principles, background and updated results of the United Kingdom systematic genome screen. Brain (1998) 1.07

Cognitive function in the Caerphilly study: associations with age social class, education and mood. Eur J Epidemiol (1999) 1.05

Lateralisation of striatal function: evidence from 18F-dopa PET in Parkinson's disease. J Neurol Neurosurg Psychiatry (2005) 1.05

Incidence of functional decline and improvement in a community-dwelling, very elderly population. Am J Epidemiol (1997) 1.05

Association analysis of 528 intra-genic SNPs in a region of chromosome 10 linked to late onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2008) 1.04

The basal ganglia and rule-governed language use: evidence from vascular and degenerative conditions. Brain (2005) 1.04

Cognitive impairment in elderly people: population based estimate of the future in England, Scotland, and Wales. BMJ (1997) 1.04

Decline across different domains of cognitive function in normal ageing: results of a longitudinal population-based study using CAMCOG. Int J Geriatr Psychiatry (2000) 1.03

Prospective association between emotional health and clinical evidence of Parkinson's disease. Eur J Neurol (2008) 1.03

The neuropathological profile of mild cognitive impairment (MCI): a systematic review. Mol Psychiatry (2011) 1.02

Socioeconomic status and the expectation of disability in old age: estimates for England. J Epidemiol Community Health (2000) 1.01

Influence of apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and smokers. Epidemiology (2000) 1.01

The use of quantitative oculometry in the assessment of Huntington's disease. Exp Brain Res (2005) 1.01

Apolipoprotein E4 is only a weak predictor of dementia and cognitive decline in the general population. J Med Genet (2002) 1.00

Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer-type pathology in the ageing brain. Neuropathol Appl Neurobiol (2009) 1.00

Microglial activation in white matter lesions and nonlesional white matter of ageing brains. Neuropathol Appl Neurobiol (2007) 1.00

Changes in self-rated health, disability and contact with services in a very elderly cohort: a 6-year follow-up study. Age Ageing (1998) 0.99

Hand tapping: a simple, reproducible, objective marker of motor dysfunction in Huntington's disease. J Neurol (2008) 0.99

Association studies of 23 positional/functional candidate genes on chromosome 10 in late-onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2007) 0.98

Saccadic latency distributions in Parkinson's disease and the effects of L-dopa. Exp Brain Res (2006) 0.98

The prevalence of vascular dementia in Europe: facts and fragments from 1980-1990 studies. EURODEM-Prevalence Research Group. Ann Neurol (1991) 0.98

APOE epsilon variation in multiple sclerosis susceptibility and disease severity: some answers. Neurology (2006) 0.97

A non-synonymous SNP within membrane metalloendopeptidase-like 1 (MMEL1) is associated with multiple sclerosis. Genes Immun (2010) 0.95

A Multiple Indicators Multiple Causes (MIMIC) model of Behavioural and Psychological Symptoms in Dementia (BPSD). Neurobiol Aging (2009) 0.94

Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. Acta Neuropathol (1998) 0.94

Vascular risk and cognitive impairment in an older, British, African-Caribbean population. J Am Geriatr Soc (2001) 0.94

Prevalence and symptomatology of depression in older people living in institutions in England and Wales. Age Ageing (2007) 0.93

Brain haemosiderin in older people: pathological evidence for an ischaemic origin of magnetic resonance imaging (MRI) microbleeds. Neuropathol Appl Neurobiol (2014) 0.93

Dura mater-associated Creutzfeldt-Jakob disease: experience from surveillance in the UK. J Neurol Neurosurg Psychiatry (2006) 0.93

Co-occurrence of anxiety and depression amongst older adults in low- and middle-income countries: findings from the 10/66 study. Psychol Med (2011) 0.93

Cellular and molecular aspects of striatal development. Brain Res Bull (2001) 0.93

The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease. Cell Transplant (2007) 0.92

The val158met COMT polymorphism's effect on atrophy in healthy aging and Parkinson's disease. Neurobiol Aging (2008) 0.92

Epidemiology of vascular dementia. Neuroepidemiology (1995) 0.92

Education and the risk for Alzheimer's disease: sex makes a difference. EURODEM pooled analyses. EURODEM Incidence Research Group. Am J Epidemiol (2000) 0.92

Neuropeptide Y and its role in CNS disease and repair. Exp Neurol (2012) 0.91

A genome screen for multiple sclerosis in Sardinian multiplex families. Eur J Hum Genet (2001) 0.91